AS
HBIO icon

Altshuler Shaham’s Harvard Bioscience HBIO Stock Holding History

Altshuler Shaham’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-609
Closed -$43K – 584
2021
Q3 		$43K Buy
+609
New +$48.5K ﹤0.01% 438

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Altshuler Shaham's HBIO Position: Q4 2021 in Review

Altshuler Shaham sold out of Harvard Bioscience (HBIO) in Q4 2021, closing a stake of 609 shares — an estimated $43K sold.

Altshuler Shaham first reported a position in HBIO in Q3 2021 and held it in 1 quarter. The position peaked at $43K in Q3 2021. 103 funds tracked by Wall St. Rank hold HBIO as of Q4 2021.

  • Altshuler Shaham reported no remaining Harvard Bioscience position as of Q4 2021 after selling out during the quarter.
  • Altshuler Shaham sold 609 Harvard Bioscience shares in Q4 2021, an estimated $43K.
  • Altshuler Shaham first reported a position in Harvard Bioscience in Q3 2021 and held it in 1 quarter.
  • Altshuler Shaham's Harvard Bioscience position peaked at $43K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2021.

Based on Altshuler Shaham's 13F filing for Q4 2021, filed 15 Feb 2022.